Muhammad Yasin, MD
Pulmonary Disease · Louisville, KYNPI 1508004094
Payments from drug & device makers
Across 65 payments — averaging $86.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Pulmonx Corporation$1K
- AstraZeneca$619
- Galvanize Therapeutics, Inc$214
- Johnson & Johnson$166
- Inari Medical, Inc.$147
- plus $792 from 12 others
What the payments were for
- Travel & lodging$1,71231%
- Food & beverage$2,36042%
- Education$1,53827%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $2,600 |
| Pulmonx Corporation | 9 | $1,072 |
| AstraZeneca(2 entities) | 8 | $619 |
| Galvanize Therapeutics, Inc | 1 | $214 |
| Johnson & Johnson | 3 | $166 |
| Inari Medical, Inc. | 1 | $147 |
| Getinge USA Sales, LLC | 2 | $143 |
| Astellas Pharma US Inc | 1 | $124 |
| Regeneron Healthcare Solutions, Inc. | 5 | $101 |
| GSK | 7 | $91 |
| Novartis | 4 | $85 |
| Genentech USA, Inc. | 3 | $66 |
| Olympus America Inc. | 1 | $58 |
| Merck | 3 | $50 |
| Boehringer Ingelheim | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,610 in reported general payments places this provider in the 50th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 535 | $438,062 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $110,653 |
| Dupixent SyringeDupilumab | 26 | $98,868 |
| Dupixent PenDupilumab | 24 | $91,380 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 93 | $81,104 |
| NucalaMepolizumab | 17 | $72,791 |
| Spiriva RespimatTiotropium Bromide | 90 | $62,792 |
| XolairOmalizumab | 12 | $61,595 |
| Breo ElliptaFluticasone/Vilanterol | 102 | $56,764 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $35,245 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $31,137 |
| SymbicortBudesonide/Formoterol Fumarate | 53 | $19,673 |
| EliquisApixaban | 11 | $18,732 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $13,126 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 362 | $11,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $91 | $609,429753 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $27 | $111,163148 claims |
| Grifols USA, LLCProlastin C | $14 | $110,65312 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $619 | $100,777146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Louisville
- John McConnellLouisville$3.5M
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
- Samantha BaahLouisville$226K
- Lebnan SaadLouisville$105K
- Josephine MeiLouisville$101K
- Tanya WieseLouisville$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.